Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-Overload congestive heart failure

Circulation: Heart Failure

Volumn 4, Issue 3, 2011, Pages 345-354

  Goltsman, Ilia ^a   Wang, Xinkang ^b   LaVallie, Edward R ^b   DiBlasio Smith, Elizabeth A ^b   Ovcharenko, Elena ^a   Hoffman, Aaron ^a   Abassi, Zaid ^a   Feuerstein, Giora Z ^b   Winaver, Joseph ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b PFIZER INC   (United States)

Author keywords

Aorto caval fistula; ECF volume expansion; rat; Renal sodium excretion; Thiazolidinedione

Indexed keywords

BIOLOGICAL MARKER; DRUG VEHICLE; PIOGLITAZONE; ROSIGLITAZONE; SODIUM CHANNEL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; SODIUM CHLORIDE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART LEFT VENTRICLE OVERLOAD; HEART VENTRICLE HYPERTROPHY; KIDNEY CLEARANCE; MALE; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SODIUM EXCRETION; SODIUM RETENTION; SODIUM TRANSPORT; SPRAGUE DAWLEY RAT; WATER RETENTION; ANIMAL; DISEASE MODEL; DRUG EFFECT; ELECTROLYTE BALANCE; HEART FAILURE; KIDNEY FUNCTION TEST; METABOLIC DISORDER; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HEART FAILURE; KIDNEY FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; THIAZOLIDINEDIONES; WATER; WATER-ELECTROLYTE BALANCE; WATER-ELECTROLYTE IMBALANCE;

EID: 79960580242     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.960179     Document Type: Article

References (41)

1. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244-251. (Pubitemid 40603072)
2. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 2000;106:1305-1307.
3. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med. 2003;115(Suppl 8A): 111S-115S.
4. Staels B. Fluid retention mediated by renal PPARgamma. Cell Metab. 2005;2:77-78.
5. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res. 2008;2008:943614.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:2457-2471. (Pubitemid 46919772)
7. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136. (Pubitemid 47464583)
8. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J. 2008;29:12-20.
9. Rosen CJ. Revisiting the rosiglitazone story: lessons learned. N Engl J Med. 2010;363:803-806.
10. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Administration. N Engl J Med. 2010; 363:1489-1491.
11. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-2948. (Pubitemid 37517824)
12. Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional class I or II heart failure. J Am Coll Cardiol. 2007;49:1696-1704. (Pubitemid 46589926)
13. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-85. (Pubitemid 37432869)
14. Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41:1394-1398. (Pubitemid 36439002)
15. Tang WH, Maroo A. PPARgamma agonists: safety issues in heart failure. Diabetes Obes Metab. 2007;9:447-454. (Pubitemid 47018508)
16. Khan O, Riazi S, Hu X, Song J, Wade JB, Ecelbarger CA. Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone. Am J Physiol Renal Physiol. 2005;289:F442-F450. (Pubitemid 41003674)
17. Riazi S, Khan O, Tiwari S, Hu X, Ecelbarger CA. Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat. Am J Nephrol. 2006;26:245-257. (Pubitemid 44114395)
18. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther. 2004;308: 426-433. (Pubitemid 38134200)
19. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11:861-866. (Pubitemid 41161118)
20. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A. 2005;102:9406-9411. (Pubitemid 40923576)
21. Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, Brown J. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 2003;17:1966-1968.
22. Artunc F, Sandulache D, Nasir O, Boini KM, Friedrich B, Beier N, Dicks E, Potzsch S, Klingel K, Amann K, Blazer-Yost BL, Scholz W, Risler T, Kuhl D, Lang F. Lack of the serum and glucocorticoidinducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone. Pflugers Arch. 2008;456: 425-436.
23. Nofziger C, Chen L, Shane MA, Smith CD, Brown KK, Blazer-Yost BL. PPARgamma agonists do not directly enhance basal or insulin-stimulated Na(+) transport via the epithelial Na(+) channel. Pflugers Arch. 2005; 451:445-453. (Pubitemid 41719576)
24. Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, Bisi J, Ashton TT, Maurio FP, Kalsi K, West TA, Baines D, Blazer-Yost BL. PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Renal Physiol. 2009;297:F55-F62.
25. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J. Thiazolidinedioneinduced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol. 2009;20:721-729.
26. Stumpe KO, Solle H, Klein H, Kruck F. Mechanism of sodium and water retention in rats with experimental heart failure. Kidney Int. 1973;4: 309-317.
27. Winaver J, Hoffman A, Burnett JC Jr, Haramati A. Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. Am J Physiol. 1988;254:R776-R784.
28. Brodsky S, Gurbanov K, Abassi Z, Hoffman A, Ruffolo RR Jr, Feuerstein GZ, Winaver J. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure. Hypertension. 1998; 32:746-752. (Pubitemid 28480555)
29. Abassi ZA, Brodsky S, Karram T, Dobkin I, Winaver J, Hoffman A. Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula. Cardiovasc Res. 2001;51:567-576. (Pubitemid 32718605)
30. Acton JJ, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, Mccann ME, Moller DE, Muise ES, Tan YG, Thompson JR, Wong KK, Wu M, Xu LB, Meinke PT, Berger JP, Wood HB. Discovery of (2R)-2-(3-{3-[(4- Methoxyphenyl)carbonyl]-2-methyl- 6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem. 2009;52:3846-3854.
31. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
32. Collins-Racie LA, Yang Z, Arai M, Li N, Majumdar MK, Nagpal S, Mounts WM, Dorner AJ, Morris E, Lavallie ER. Global analysis of nuclear receptor expression and dysregulation in human osteoarthritic articular cartilage: reduced LXR signaling contributes to catabolic metabolism typical of osteoarthritis. Osteoarthritis Cartilage. 2009;17: 939-949.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. (Pubitemid 34164012)
34. Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res. 2008;57: 383-392.
35. Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, Okada-Iwabu M, Ueki K, Kadowaki T. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. J Biol Chem. 2009;284: 30049-30057.
36. Geng DF, Wu W, Jin DM, Wang JF, Wu YM. Effect of peroxisome proliferator-activated receptor gamma ligand: rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol. 2006;113:86-91. (Pubitemid 44648366)
37. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132. (Pubitemid 35440299)
38. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker Fatty rat heart. Diabetes. 2002;51:1110-1117. (Pubitemid 34438357)
39. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/ reperfusion-induced myocardial injury. Diabetes. 2005;54:554-562.
40. Goenka N, Kotonya C, Penney MD, Randeva HS, O'Hare JP. Thiazolidinediones and the renal and hormonal response to water immersioninduced volume expansion in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2008;294:E733-E739. (Pubitemid 351483598)
41. Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M, Takahashi J, Della Vecchia K, Kondo T, Aiello LP, King GL. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR gamma agonist's effects on edema and weight gain. FASEB J. 2006;20: E367-E380. (Pubitemid 44943872)